River blindness in Africa - PowerPoint PPT Presentation

About This Presentation
Title:

River blindness in Africa

Description:

River blindness in Africa Presented By Grace Salako Smith Walden University Ph.D Public Health Student. The Disease and its Cause Onchocerciasis or river blindness ... – PowerPoint PPT presentation

Number of Views:397
Avg rating:3.0/5.0
Slides: 21
Provided by: eliseco
Category:

less

Transcript and Presenter's Notes

Title: River blindness in Africa


1
River blindness in Africa
  • Presented By
  • Grace Salako Smith
  • Walden University
  • Ph.D Public Health Student.

2
The Disease and its Cause
  • Onchocerciasis or river blindness, is the world's
    second leading infectious cause of blindness. A
    parasitic disease with an insect vector -
    blackfly (Simulium). that breeds in water. The
    blackfly lays its eggs in the water of
    fast-flowing rivers, these mature into adult
    blackflies in 8 to 12 days. The female blackfly
    typically seeks a bloodmeal after mating and,
    upon biting a person who is infected with
    onchocerciasis, may ingest worm larvae, which can
    then be passed on to the next person bitten by
    the blackfly. Eventually, the transmitted worm
    larvae develop into adult worms and settle into
    fibrous nodules in the human body close to the
    surface of the skin or near the joints.
    Onchocerca volvulus, the parasitic worm can live
    for up to 14 years in the human body.
  • Retrieved from http//www.worldwaterday.org/wwday/
    2001/disease/oncho.html

3
29 Symptoms of River Blindness Disease
  • Severe itching initially in one section of body
    then spreading to whole body and eyes
  • Skin nodules Lymphadenitis
    Lichenified skin Loss of skin
  • pigmentation Excessive skin pigmentation
    Photophobia
  • Corneal inflammation Iris inflammation
    Retinal inflammation
  • Choroid inflammation Optic nerve inflammation
    Eosinophilia
  • Urticarial (hives-like) rash Swelling of
    limbs (oedema) Spotty skin Bleeding patches
  • From Tough and wrinkled skin Enlarged groin
    lymph nodes Fluid swellings of testes
    (hydrocoele Elephantiasis of scrotum) Itchy
    red eyes Excessive tear formation
  • Cataracts Blurred vision Loss of vision
    Nodules under skin Skin rash Itchy skin

4
Life cycle of Onchocerca volvulus
5
Worldwide Occurence and Distribution
6
(No Transcript)
7
Faces of the Victims
8
An Infected Eye and Victims
9
Environmental Epidemiology
  • Despite success in West Africa, 109 million
    people remain at risk of contracting river
    blindness in the 19 countries of Central, Eastern
    and Southern Africa.
  • This is due to the infestation of fast flowing
    streams and rivers polluted by raw sewage
    untreated solid and liquid waste which provide a
    great breeding place for blackflies.

10
Incidence and Morbidity
  • In recent decades, onchocerciasis has struck some
    18 million people worldwide, and accounts for
    nearly a tenth of all cases of blindness. The
    vast majority of river blindness cases have been
    in sub-Saharan Africa, where nearly 30 countries
    have been affected.
  • Reference.
  • Laolu Akande (2003) Victory over river
    blindness.Success of "big dream" is a model for
    other African health campaigns. Africa Recovery,
    Vol.17 1 (May 2003), page 6

11
Current Status of Disease in Africa
  • The WHO program treats nearly 54 million people
    annually in 15 countries. It has achieved a 30
    percent reduction in the prevalence of infection,
    and a 55 percent reduction in itching. The rates
    of impaired vision and blindness have dropped by
    35 percent.
  • The WHO tries to get national government to take
    over funding the programs once they are up and
    running, but that can be difficult because
    Onchocerciasis is not high up on the budget list
    compared to HIV/AIDS and tuberculosis.

12
Current treatment
  • 30-year campaign against river blindness, known
    as the Onchocerciasis Control Programme (OCP),
    formally concluded in December 2002. free dose of
    the drug Mectizan, donated by the US
    pharmaceutical company Merck, in time to prevent
    the disease from reaching its mature stage, when
    irreversible blindness can occur.. The World
    Health Organization (WHO) estimates that the
    effort has prevented 600,000 new cases of the
    disease.

13
Current Treatment challenges
  • "Onchocerciasis is a forgotten disease," "It
    needs more attention and it is a disease which we
    can eliminate if more effort is put into it."
  • Although Ivermectin, manufactured by Merck is
    effective, it can be difficult to convince people
    to take it.This is because the drug does not kill
    the adult worms, but reduces their breeding rate
    and kills off their belligerent offspring. When
    sufferers first take the drug, it can produce
    severe itching and swelling, as the baby worms
    inside the body die off.
  • The drug must be taken annually for the life of
    the adult worm, which is about 15 years.
    Furthermore, everyone in the village must take
    the drug with the exception of small children,
    the very ill and pregnant and nursing women or
    else the worms will continue to breed and can re
    infect the population.
  • Additionally, people frequently stop taking the
    drug once the symptoms of the disease subside,
    often after several years of treatment, said
    Tanzanias minister of health and social welfare,
    David Mwakyusa.
  • http//www.globalpost.com/

14
Intervention Background Information
  • In 2005 alone, the river blindness control
    program helped to treat over 35 million people
    against the disease in Central, Eastern and
    Southern Africa.
  • Over the last 30 years, CIDA has committed more
    than US25 million to international efforts to
    fight river blindness in Africa. Since 2002,
    Canada has ranked as one of the top five donors
    worldwide.
  • CIDA funding is currently providing
    community-based drug treatment programs for
    infected patients.
  • Source http//www.acdi-cida.gc.ca/cidaweb/acdicid
    a.nsf/En/FRA-1012103248-K3K

15
Current Donors and organizations
  • The Carter Center's River Blindness Program
    distributes Ivermectin to control or eliminate
    river blindness, also known as onchocerciasis The
    program aims to eliminate the disease in 13
    endemic areas in the Americas as well as parts of
    Uganda and Sudan. It also aims to control the
    disease in Nigeria, Ethiopia, Cameroon, Uganda,
    and Sudan.
  • The Carter Center receives donated ivermectin
    from Merck, and then follows the
    "Community-Directed Treatment with Ivermectin
    Process"

16
Other Donors The World Bank.
  • APOC is based on Mectizan (ivermectin)
    distribution. This drug was developed by Merck
    Co. in the 1980s and is now donated for
    riverblindness control. Mectizan is distributed
    by communities themselves, trained and supported
    by the riverblindness partners, including
    international agencies, participating country
    governments, NGDOs, donor countries, and of
    course, the communities themselves. APOC was
    tested and validated on a local basis and has
    been scaled up by continually launching more
    projects. From modest beginnings in 1996, it is
    estimated that by 2007, 65 million people will be
    reached annually through this program. The
    distribution network is also being tested to
    deliver other interventions. This enticing
    possibility opens the door to further scaling up
    and presents the opportunity to deliver other
    basic health interventions in the riverblindness
    areas, which are almost exclusively remote,
    rural, and poor. Most are not reached by other
    programs and some are not reached by the national
    governments.
  • Source The World Bank Group. Global
    Partnership to Eliminate River blindness
    retrieved from
  • http//www.worldbank.org/afr/gper/

17
Donor Activity
  • Center Partners Increase Program ReachThe Carter
    Center's River Blindness Program works through
    partnerships at all levels. The primary partners
    are the people in the afflicted communities, who
    organize themselves and volunteer their time to
    help distribute Mectizan.  The Lions Clubs
    International Foundation, a longtime partner in
    the fight against river blindness, has provided
    The Carter Center with grants since 1996 to
    prevent the disease in Africa and the Americas.
    The River Blindness Program supports the
    ministries of health and their national
    onchocerciasis control efforts executed within
    and through national primary public and community
    health care systems. The Carter Center also works
    closely with the Centers for Disease Control and
    Prevention and the Mectizan Donation
    Program. The River Blindness Program partners
    in Africa include the ministries of health in the
    five endemic countries, the United Nations and
    affiliated organizations (the World Health
    Organization, the World Bank, and UNICEF), and
    other nongovernmental development organizations.
    Another important partner is the African
    Programme for Onchocerciasis Control, which is
    executed by WHO and funded through a World Bank
    trust fund. In Latin America, OEPA's
    partnerships include the ministries of health in
    the six endemic countries, the Pan American
    Health Organization, the Centers for Disease
    Control and Prevention, academic institutions
    (such as The Scripps Research Institute), and
    independent organizations.
  • The Carter Center (2009) Center Partners Increase
    Program ReachRetrieved on July 14, 2009 from
    www.cartercenter.org

18
Success Story
  • Cameroon is one of the West African countries
    where River Blindness has been wiped out.
  • Source Canada Agency for International
    Development (2009) River Blindness In West Africa
    Is Nearly Eradicated, Canada Is Key Donor To
    Expansion Efforts Across Africa

19
Possible Solution?Treatment Drug in clinical
trials
  • A drug normally used in animals will be tested
    for its ability to control river blindness
    transmission in clinical trials in the Democratic
    Republic of Congo (DRC), Ghana and Liberia.The
    phase III trials, launched (1 July, 2008) at the
    World Conference of Science Journalists in
    London, United Kingdom, will assess the
    effectiveness of moxidectin in preventing
    transmission of the worms which cause river
    blindness, or onchocerciasis one of the leading
    infectious causes of blindness in Africa.
  • The trials will last for the next two and a half
    years and will be run by the WHO Special
    Programme for Research and Training in Tropical
    Diseases (WHO/TDR), and Wyeth Pharmaceuticals,
    the company behind the drug. Fifteen hundred
    people at four sites in the three countries will
    be involved.
  • Source Voices from Ghana retrieved from
    http//ghanavoices.files.wordpress.com/2009/07/riv
    er-blindness-2.gifimgrefurl

20
NEEDS
  • More financial support for non governmental and
    other Institutions to increase public health
    education especially in the rural areas.
  • Clean and potable water both surface and
    underground (boreholes) for the poor people in
    African countries like Zambia, Tanzania and Mali
    so the people with have little contact with the
    river and the blackflies that transmit the
    disease.
Write a Comment
User Comments (0)
About PowerShow.com